创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the characteristics of iHuPDX model

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-29 15:17
  • Views:

(Summary description)With the rapid development of the biomedical field, there is a growing demand for precision and individualization of disease models. Against this background, the iHuPDX model developed by InnoModels Biotechnology has become a shining star in the field of drug efficacy evaluation due to its unique individualized features and excellent stability. In this paper, we will introduce the features of iHuPDX model in depth and lead readers to explore its unlimited potential in pharmaceutical research.

InnoModels Biotechnology: What are the characteristics of iHuPDX model

(Summary description)With the rapid development of the biomedical field, there is a growing demand for precision and individualization of disease models. Against this background, the iHuPDX model developed by InnoModels Biotechnology has become a shining star in the field of drug efficacy evaluation due to its unique individualized features and excellent stability. In this paper, we will introduce the features of iHuPDX model in depth and lead readers to explore its unlimited potential in pharmaceutical research.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-29 15:17
  • Views:
Information

With the rapid development of the biomedical field, there is a growing demand for precision and individualization of disease models. Against this background, the iHuPDX model developed by InnoModels Biotechnology has become a shining star in the field of drug efficacy evaluation due to its unique individualized features and excellent stability. In this paper, we will introduce the features of iHuPDX model in depth and lead readers to explore its unlimited potential in pharmaceutical research.
First of all, the iHuPDX model is a xenotransplantation technique based on individual patient tumor cells. This technology forms highly individualized transplanted tumors by collecting cancer tissue samples from patients and transplanting them into animals such as mice. This model not only simulates the real growth environment of the patient's tumor, but also preserves the original biological characteristics of the tumor cells, making the experimental results closer to the actual situation of the patient. Therefore, iHuPDX model plays a pivotal role in the development of precision medicine and personalized treatment plans.
Secondly, iHuPDX model has highly individualized characteristics. Each patient's tumor cells are unique, so the iHuPDX model based on individual patient tumor cells can restore the patient's tumor characteristics to the greatest extent. This individualization feature allows the model to excel in drug response prediction. With the iHuPDX model, researchers can test the response of different drugs to a specific patient's tumor, thereby tailoring a personalized treatment plan for the patient. This precise treatment approach is expected to significantly increase the success rate of treatment, reduce side effects and improve patients' quality of life.

 


In addition, the iHuPDX model has excellent stability and growth rate. With advanced primary cell inoculation technology, the model is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is ensured through the cell suspension modeling approach, resulting in a high degree of consistency in the growth rate and biological characteristics of the model. This stability not only ensures the reliability of the experimental results, but also reduces the experimental and time costs, providing researchers with a more efficient and convenient experimental platform.
Finally, it is worth mentioning that the iHuPDX model also provides a new perspective for cancer research. With the help of this highly individualized disease model, researchers can explore more deeply the differences in tumor heterogeneity among different patients and reveal the diversity of cancers. This will help us better understand the mechanisms of cancer occurrence and provide important information for the development of individualized treatment strategies.
In summary, the iHuPDX model of InnoModels Biotechnology has shown great potential and value in the field of drug efficacy evaluation by virtue of its individualized features, excellent stability and growth rate, and the new perspective it provides for cancer research. With the continuous development and improvement of the technology, it is believed that the iHuPDX model will bring benefits to more patients in the future, and drive the biomedical field towards a new era of greater precision and efficiency.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司